As of August 28, 2026, Lisata Therapeutics, Inc. (LSTA) has a DilutionWatch DilutionScore of 52/100, rated HIGH dilution risk. Lisata Therapeutics, Inc. has a market capitalization of $29.60M, 9.01M shares outstanding.
This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.
Dilution Forecast
⛅
Watch
Minor dilution signals detected
model est. 22%
💰 Capital Raise
model 35%
• Low cash runway: 5 months remaining
🔄 Reverse Split
model est. 15%
• Only 5 months cash — financial pressure
Market Data
Market Cap$29.60M
Shares Outstanding9.01M
Float7.19M
Cash$10.44M
DebtN/A
Short InterestN/A
Institutional Holdings
11.3% institutional ownership
Source: Yahoo Finance · Detailed 13F holder data available for tracked tickers
Short Interest
Short Interest56.3K
Days to Cover1.0
% of Float0.8%
FINRA data as of Jul 31, 2026
Recent SEC Activity
xbrl
XBRL CONVERTIBLE
2010-12-31
4
INSIDER TRANSACTION
2026-01-13
4
INSIDER TRANSACTION
2026-01-13
4
INSIDER TRANSACTION
2026-01-13
4
INSIDER TRANSACTION
2026-01-13
Full SEC filing analysis available with free account
→
Recent News
No recent news
Factual LSTA Dilution Snapshot
Lisata Therapeutics, Inc. (LSTA) has a DilutionScore of 52/100, rated High dilution risk. Score date: August 28, 2026.
- Recent SEC activity tracked for LSTA: 4 on 2026-01-13; 4 on 2026-01-13; 4 on 2026-01-13.
This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.
Track LSTA Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking LSTA — Free
Real-time SEC alerts
DilutionScore™ tracking
No credit card required
More Research for LSTA
Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.